Metformin increases the novel adipokine cartonectin/ctrp3 in women with polycystic ovary syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 12, 2013, Pages

  Tan, Bee K ^a   Chen, Jing ^a   Hu, Jiamiao ^a   Amar, Omar ^a   Mattu, Harman S ^a   Adya, Raghu ^a   Patel, Vanlata ^a   Ramanjaneya, Manjunath ^b   Lehnert, Hendrik ^a,b   Randeva, Harpal S ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ANDROSTENEDIONE; C REACTIVE PROTEIN; CARTONECTIN; ESTRADIOL; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; METFORMIN; PRASTERONE SULFATE; TESTOSTERONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; NAUSEA; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS; SUBCUTANEOUS FAT; WAIST HIP RATIO; YOUNG ADULT;

ADIPOKINES; ADULT; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIC AGENTS; METFORMIN; OMENTUM; OVERWEIGHT; POLYCYSTIC OVARY SYNDROME; SUBCUTANEOUS FAT, ABDOMINAL; TISSUE CULTURE TECHNIQUES; TUMOR NECROSIS FACTORS; UP-REGULATION;

EID: 84890171844     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2227     Document Type: Article

References (29)

1. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997; 18:774-800.
2. Wild RA, Painter RD, Coulson PB, Carruth KB, Ranney RB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1985;61:946- 951.
3. Diamanti-Kandarakis E. Insulin resistance in PCOS. Endocrine. 2006;30:13-17.
4. Diamanti-Kandarakis E, Paterakis T, Kandarakis HA. Indices of low-grade inflammation in polycystic ovary syndrome. Ann NY Acad Sci. 2006;1092:175-186.
5. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548-2556.
6. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000;21:697-738.
7. Thorne A, Lonnqvist F, Apelman J, Hellers G, Arner P.Apilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. Int J Obes Relat Metab Disord. 2002;26:193-199.
8. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumour necrosis factor-α: direct role in obesity-linked insulin resistance. Science. 1993;259:87-91.
9. Kubaszek A, Pihlajamäki J, Komarovski V, et al. Promoter polymorphisms of the TNF-α (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes. 2003;52:1872- 1876.
10. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-126.
11. Peterson JM, Wei Z, Wong GW. C1q/TNF-related protein-3 (CTRP3), a novel adipokine that regulates hepatic glucose output. J Biol Chem. 2010;285:39691-39701.
12. Kopp A, Bala M, Weigert J, et al. Effects of the new adiponectin paralogous protein CTRP-3 and of LPS on cytokine release from monocytes of patients with type 2 diabetes mellitus. Cytokine. 2010; 49:51-57.
13. Kopp A, Bala M, Buechler C, et al. C1q/TNF-related protein-3 represents a novel and endogenous lipopolysaccharide antagonist of the adipose tissue. Endocrinology. 2010;151:5267-5278.
14. Hofmann C, Chen N, Obermeier F, et al. C1q/TNF-related protein- 3 (CTRP-3) is secreted by visceral adipose tissue and exerts antiinflammatory and antifibrotic effects in primary human colonic fibroblasts. Inflamm Bowel Dis. 2011;17:2462-2471.
15. Yi W, Sun Y, Yuan Y, et al. C1q/tumor necrosis factor-related protein- 3, a newly identified adipokine, is a novel antiapoptotic, proangiogenic, and cardioprotective molecule in the ischemic mouse heart. Circulation. 2012;125:3159-3169.
16. Fauser B. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome (PCOS).Hum Reprod. 2004;19:41-47.
17. Fried SK, Moustaid-Moussa N. Culture of adipose tissue and isolated adipocytes. Methods Mol Biol. 2001;155:197-212.
18. Choi KM, Hwang SY, Hong HC, et al. C1q/TNF-related protein-3 (CTRP-3) and pigment epithelium-derived factor (PEDF) concentrations in patients with type 2 diabetes and metabolic syndrome. Diabetes. 2012;61:2932-2936.
19. Yoo HJ, Hwang SY, Hong HC, et al. Implication of progranulin and C1q/TNF-related protein-3 (CTRP3) on inflammation and atherosclerosis in subjects with or without metabolic syndrome. PLoS One. 2013;8:e55744.
20. Molavi B, Rassouli N, Bagwe S, Rasouli N. A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications. Vasc Health Risk Manag. 2007;3:967-973.
21. WongGW,Krawczyk SA, Kitidis-Mitrokostas C, Revett T, GimenoR, Lodish HF. olecular, biochemical and functional characterizations of C1q/TNF family members: adipose-tissue-selective expression patterns, regulation by PPAR-α agonist, cysteine-mediated oligomerizations, combinatorial associations and metabolic functions. Biochem J. 2008;416:161-177.
22. Schmid A, Kopp A, Hanses F, Bala M, Müller M, Schäffler A. The novel adipokine C1q/TNF-related protein-3 is expressed in human adipocytes and regulated by metabolic and infection-related parameters. Exp Clin Endocrinol Diabetes. 2012;120:611-617.
23. Arner P. Effects of testosterone on fat cell lipolysis. Species differences and possible role in polycystic ovarian syndrome. Biochimie. 2005;87:39-43.
24. Johnson AB, Webster JM, Sum CF, et al. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. Metabolism. 1993;42:1217-1222.
25. Perriello G, Misericordia P, Volpi E, et al. Acute antihyperglycemic mechanisms of metformin in NIDDM: evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes. 1994;43: 920-928.
26. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 1998;338:867-872.
27. Lihn AS, Jessen N, Pedersen SB, Lund S, Richelsen B. AICAR stimulates adiponectin and inhibits cytokines in adipose tissue. Biochem Biophys Res Commun. 2004;316:853-858.
28. Sell H, Dietze-Schroeder D, Eckardt K, Eckel J. Cytokine secretion by human adipocytes is differentially regulated by adiponectin, AICAR, and troglitazone. Biochem Biophys Res Commun. 2006; 343:700-706.
29. Palomba S, Falbo A, Giallauria F, et al. Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome. Diabetes Care. 2010;33:246-251.